Evaluate Companies

 
News Articles for Evaluate Companies top ^
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0971593001&sourceType=1 VANCOUVER, BRITISH COLUMBIA --
Sign-up for GVIC Acquires Majority Interest in Evaluate Energy investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0971592001&sourceType=1 http://www.ccnmatthews.com/logos/20081113-gvc.gif VANCOUVER, BRITISH COLUMBIA --
Sign-up for Glacier Acquires Majority Interest in Evaluate Energy investment picks
Infoblox Inc. (NYSE:BLOX), the network control company, today introduced a free DNS-based evaluation product to help find malware carefully hidden by cybercriminals inside enterprise networks.
Sign-up for You’ve Got Malware: Infoblox Introduces Free Product Evaluation to Find the DNS Footprints of Cybercrime Inside Enterprise Networks investment picks
ICF International (NASDAQ:ICFI), a leading provider of consulting services and technology solutions to government and commercial clients, has won a re-compete agreement – as part of a consortium led by the Carolina Population Center at the University of North Carolina – to support the U.S. Agency for International Development (USAID) MEASURE Evaluation Phase IV program.
Sign-up for ICF International Wins Re-competes as Key Consortium Members on USAID’s MEASURE Evaluation Phase IV Program and Maternal and Child Survival Program investment picks
2014/9/30
ELKHART, Ind.
Sign-up for Skyline Corporation Comments On Its Ongoing Evaluation Of Strategic Initiatives investment picks
Fiserv , Inc. (NASDAQ: FISV), a leading global provider of financial services technology solutions, announced today that its Mobiliti TM mobile banking solution was named the market leader in the just-published “ Ovum Decision Matrix: Selecting the Next Generation Mobile Banking Solution .” The report evaluated eight global mobile banking providers based on market impact, technology and execution.
Sign-up for Mobiliti from Fiserv Recognized as the Market Leader in Ovum Global Mobile Banking Vendor Evaluation investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1159279&ProfileId=051205&sourceType=1 BAIE VERTE, NL --
Sign-up for Rambler and Maritime Agree to Evaluate the Viability of Restarting the Past Producing Hammerdown Gold Mine investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb’s investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R). The Phase 1a/1b study will evaluate the combination of Opdivo and FPA008 as a potential treatment option for patients with non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, pancreatic cancer, colorectal cancer and malignant glioma.
Sign-up for Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types investment picks
Study is the First to Evaluate Investigational Combination of an Oncolytic Immunotherapy and Anti-PD-1 Therapy THOUSAND OAKS, Calif.
Sign-up for New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G021941-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/9/16/11G021941/Rackspace_logo_No_1_Mgd_small_use_color-1964618605.jpg SAN ANTONIO, TX--(Marketwired - September 16, 2014) - Rackspace® (NYSE: RAX), the #1 managed cloud company, today announced it has ended its evaluation of alternatives that would result in Rackspace being acquired.
Sign-up for Rackspace Ends Formal Evaluation of M&A Transactions; Focus Remains on Managed Cloud Market Leadership investment picks
The Babcock & Wilcox Company (B&W) (NYSE:BWC) today announced that its Board of Directors is evaluating the separation of the Company’s Power Generation Business and Government & Nuclear Operations Business into two publicly traded companies.
Sign-up for B&W Evaluating a Separation of Its Businesses investment picks
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has successfully completed Cohort 6 of its Phase I clinical trial evaluating lead compound, Liposomal Grb-2, in blood cancers.
Sign-up for Bio-Path Holdings Successfully Completes Cohort 6 of Phase I Clinical Trial Evaluating Liposomal Grb-2 in Blood Cancers investment picks
Bristol-Myers Squibb Company (NYSE:BMY) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of combining Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) with three molecularly targeted oncology therapies ( Zykadia (ceritinib), INC280 and EGF816) from Novartis (NYSE: NVS). Novartis will conduct two Phase 1/2 studies focused on non-small cell lung cancer (NSCLC). “Bristol-Myers Squibb is committed to advancing the science, research and development of immunotherapy as an innovative approach to treating cancer in multiple tumor types,” said Michael Giordano, senior vice president, Oncology Development, Bristol-Myers Squibb.
Sign-up for Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo (nivolumab) in Combination with Targeted Therapies from Novartis to Treat Non-Small Cell Lung Cancer (NSCLC) investment picks
Bristol-Myers Squibb Company (NYSE:BMY), Pharmacyclics, Inc. (NASDAQ:PCYC), and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO ® (nivolumab) in combination with IMBRUVICA ® (ibrutinib), an oral Bruton's tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen.
Sign-up for Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma investment picks
Pfizer Inc. (NYSE:PFE) announced today that it will present data from a Phase 1/Phase 2 study evaluating the safety, tolerability and immunogenicity of a single-dose vaccine of Pfizer’s investigational 4-antigen Staphylococcus aureus ( S.
Sign-up for Pfizer to Present New Data Evaluating Safety, Tolerability and Immunogenicity of its Investigational Staphylococcus aureus Vaccine Candidate at IDWeek 2014™ investment picks
New evaluation module features TI's smallest HD pico display chipset, resulting in brighter, more efficient displays DALLAS , Nov.
Sign-up for TI DLP® LightCrafter™ Display 3010 evaluation module enables HD projection in compact electronics investment picks
2014/11/4
PhotoMedex, Inc. (NasdaqGS and TASE:PHMD) announces the Company has entered into an Amended and Restated Forbearance Agreement (the "Amended Forbearance Agreement") with respect to its Credit Agreement dated May 12, 2014 and the Initial Forbearance Agreement dated August 25, 2014 by and among PhotoMedex, Inc. as borrower and the Lenders as parties thereto, and JPMorgan Chase Bank, N.A. (the "Administrative Agent"), acting on behalf of secured creditors as the administrative agent.
Sign-up for PhotoMedex Agrees to Amended Forbearance Agreement with Secured Creditors, Engages Canaccord Genuity to Evaluate Strategic Alternatives investment picks
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the last patient has been enrolled in a double-blind, multiple-dose, phase 3 study to evaluate the efficacy and safety of QuickShot ® Testosterone (QS T) administered subcutaneously once each week to testosterone-deficient adult males.
Sign-up for Antares Pharma Announces Last Patient Enrolled in Phase 3 QuickShot® Study Evaluating Testosterone-Deficient Adult Males investment picks
By Angela Chen Alliant Techsystems Inc. said it is evaluating any potential implications from Tuesday night's explosion of Orbital Sciences Inc.'s Antares rocket, a hint their plans to merge could be in jeopardy.
Sign-up for Alliant Tech evaluating merger plans after Orbital rocket explosion investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Evaluate Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: European Technology  |  Next: Evaluating Strategic Alternatives